Baran Akagunduz, Fatih Ozcicek, Ali Veysel Kara, Deniz Can Guven, Gulce Naz Yazici, Abdulkadir Çoban, Bahadır Suleyman, Renad Mammadov, Halis Suleyman
PURPOSE: Vandetanib is a wide spectrum tyrosine kinase inhibitor used for the treatment of metastatic medullary thyroid cancer (MTC) and various other cancer types. Although it is usually well-tolerated ıt has been linked to a variety of severe dermatologic reactions. Our study aimed was to investigate adenosine 5'-triphosphate (ATP) on vandetanib-induced skin damage. MATERIALS AND METHODS: A total number of 18 rats were divided into three equal groups as vandetanib group (VDB), vandetanib plus ATP group (VAT), and healthy group (HG); 25 mg/kg ATP was injected intraperitoneally (ip) to the VAT group...
December 2020: Cutaneous and Ocular Toxicology